Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.8K
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

513
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
513
Retroviruses02:33

Retroviruses

14.3K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
14.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selection of Mutations in HIV-1 Nucleocapsid and Integrase in Individuals Living with HIV Experiencing Virologic Failure After Initiating or Switching to Tenofovir-Lamivudine-Dolutegravir.

medRxiv : the preprint server for health sciences·2026
Same author

Mechanisms of HIV-1 assembly, release and maturation.

Nature reviews. Microbiology·2026
Same author

A mechanism-aware stoichiometry platform resolves functional viral thresholds and induces antiviral hypersensitivity.

bioRxiv : the preprint server for biology·2026
Same author

Elucidating the Mechanism by Which HIV-1 Nucleocapsid Mutations Confer Resistance to Integrase Strand Transfer Inhibitors.

bioRxiv : the preprint server for biology·2025
Same author

IFN-inducible Human Phospholipid Scramblase 1 (PLSCR1) Protein Restricts HIV-1 Infection by Inhibiting Membrane Fusion.

bioRxiv : the preprint server for biology·2025
Same author

IFN-inducible human phospholipid scramblase 1 (PLSCR1) protein restricts HIV-1 infection by inhibiting membrane fusion.

Proceedings of the National Academy of Sciences of the United States of America·2025

Related Experiment Video

Updated: Dec 10, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.2K

HIV-1 Maturation: Lessons Learned from Inhibitors.

Alex B Kleinpeter1, Eric O Freed1

  • 1HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.

Viruses
|August 30, 2020
PubMed
Summary

New HIV-1 maturation inhibitors (MIs) offer novel therapeutic strategies by targeting distinct steps in viral development. These compounds, including CA-SP1 processing inhibitors, CA-binding inhibitors, and allosteric integrase inhibitors, block capsid formation and viral infectivity.

Keywords:
ALLINIGagHIV-1assemblycapsidcapsid inhibitormaturationmaturation inhibitor

More Related Videos

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

6.8K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.7K

Related Experiment Videos

Last Updated: Dec 10, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.2K
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

6.8K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.7K

Area of Science:

  • Virology and Molecular Biology
  • Drug Discovery and Development
  • Structural Biology

Background:

  • Combination antiretroviral therapy (cART) has significantly improved HIV-1 management but faces challenges like virologic failure and toxicity.
  • Current HIV-1 therapies primarily target early replication steps, with protease inhibitors acting at the maturation stage.
  • HIV-1 maturation is a critical process involving Gag polyprotein processing and capsid structural rearrangement for infectivity.

Purpose of the Study:

  • To review the development and therapeutic potential of HIV-1 maturation inhibitors (MIs).
  • To highlight insights into HIV-1 biology and structure gained from studying MIs.
  • To categorize MIs based on their distinct mechanisms of action against HIV-1 maturation.

Main Methods:

  • Review of scientific literature on HIV-1 maturation inhibitors.
  • Categorization of inhibitors based on their molecular targets and mechanisms.
  • Analysis of structural and biological insights derived from MI research.

Main Results:

  • Identification of three distinct classes of MIs: CA-SP1 processing inhibitors, CA-binding inhibitors, and allosteric integrase inhibitors (ALLINIs).
  • All reviewed MI classes effectively block the formation of the condensed conical capsid.
  • MIs disrupt critical steps in HIV-1 maturation, leading to non-infectious viral particles.

Conclusions:

  • Maturation inhibitors represent a promising, mechanistically distinct class of anti-HIV-1 compounds.
  • The study of MIs has provided crucial understanding of HIV-1 replication and structure.
  • Diversifying HIV-1 treatment strategies with MIs is essential to overcome therapeutic resistance and toxicity.